Is NNOX a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Differentiated imaging technology, with revenue (ttm) at ~$15.6 million (Q2 2026: ~$4.2 million, +37% YoY). The bear case rests on the dominant risk is that Nano-X is early-commercial and unprofitable, with tiny revenue relative to its spending and ongoing cash burn, and dilution is already happening: after Q2 2026 it raised $8.5 million through a registered direct offering and its at-the-market program and said it intends to continue raising funds. Analysts covering it are spread from $3.00 to $5.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is that Nano-X is early-commercial and unprofitable, with tiny revenue relative to its spending and ongoing cash burn, and dilution is already happening: after Q2 2026 it raised $8.5 million through a registered direct offering and its at-the-market program and said it intends to continue raising funds. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $3.00, +566.7% from the $0.45 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Differentiated imaging technology. Nano-X's digital, semiconductor-based X-ray source aims to be cheaper and more compact than the conventional X-ray tubes that dominate the industry. The most optimistic analyst target on NNOX is $5.00, +1011.1% from the $0.45 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is that Nano-X is early-commercial and unprofitable, with tiny revenue relative to its spending and ongoing cash burn, and dilution is already happening: after Q2 2026 it raised $8.5 million through a registered direct offering and its at-the-market program and said it intends to continue raising funds. With cash near $31 million at June 30, 2026 and first-half operating outflow of about $25.5 million, the runway is short without more capital. Selling shares at under $1 dilutes heavily, and a sustained bid price below $1 can put a Nasdaq listing at risk under the exchange's minimum bid rules, which companies typically address with a reverse split (the Q2 release did not mention a notice). Commercialization has repeatedly taken longer than hoped, the company gives no revenue guidance, and the $40.7 million AI impairment cut the value placed on one of its main revenue lines. A securities class action filed June 12, 2026 covers buyers from March 2025 to April 2026. The technology, while novel, must prove durable, cost-effective, and clinically accepted against entrenched incumbents with vastly larger scale and installed bases. Regulatory, reimbursement, manufacturing, and service-network hurdles are significant barriers. The stock has a history of sharp price swings and has drawn skepticism from short sellers questioning the technology and timeline, and there is real risk the company does not reach self-sustaining scale. The most pessimistic published target is $3.00, +566.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Nano-X Imaging Ltd is a medical-imaging technology company, headquartered in Israel, developing and commercializing a new approach to X-ray imaging.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Differentiated imaging technology) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is that Nano-X is early-commercial and unprofitable, with tiny revenue relative to its spending and ongoing cash burn, and dilution is already happening: after Q2 2026 it raised $8.5 million through a registered direct offering and its at-the-market program and said it intends to continue raising funds) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice; Walnut is not an investment adviser. The bull case is a differentiated X-ray technology, a growing set of FDA clearances, new distribution partnerships, and recurring AI and teleradiology revenue that grew 37% in Q2 2026. The bear case is that the company is unprofitable, had about $31 million of cash at mid-year, is actively selling stock below $1 a share, wrote down its AI business by $40.7 million, and competes against far larger incumbents. This is a speculative, high-risk name.

Nano-X develops medical-imaging technology centered on a novel digital X-ray source and its Nanox.ARC multi-source tomosynthesis systems, which produce 3D-style images. It also runs an AI radiology business (Nanox.AI) that flags findings in scans and a teleradiology service connecting facilities with remote radiologists. The goal is to make imaging cheaper and more accessible, though the hardware business is still early in commercialization and teleradiology produces most current revenue.

Nano-X is a pre-profit company whose value depends on future execution rather than current earnings. News about FDA clearances, deployment partnerships, cash burn, capital raises, and guidance changes can each move the shares sharply because they change the perceived odds of the company reaching scale. In 2026 the moves have mostly been down: about -83% year to date through October 16, including a 35% drop in the final month, as the company disclosed a large impairment and new share sales.